Myriad Genetics (NASDAQ: MYGN) and SOPHiA Genetics (NASDAQ: SOPH) announced a collaboration to advance a prostate cancer-specific genomic instability score (PrGIS) technology, working alongside AstraZeneca (NYSE: AZN) to support precision oncology approaches.

PrGIS is a biomarker signature designed to assess chromosomal instability associated with homologous recombination deficiency (HRD) in prostate cancer patients. Myriad developed the technology using its MyChoice CDx test, currently available as a companion diagnostic in ovarian cancer, which will produce the PrGIS score as the company pursues prostate cancer as a new indication.

The collaboration aims to advance PrGIS in clinical trials and expand access to precision oncology medicines through potential companion diagnostic solutions. SOPHiA Genetics is developing its solid tumor application for Extended Homologous Recombination Solution into a decentralized companion diagnostic solution that will incorporate Myriad's PrGIS technology. SOPHiA Genetics operates a cloud-based platform connected to more than 1,000 institutions across over 75 countries.

"This collaboration showcases Myriad's biopharma capabilities to support development of precision oncology treatments," said Lou Welebob, Senior Vice President, Companion Diagnostics, Myriad Genetics.

"Precision medicine has a geographic problem because breakthrough therapies developed in major markets often remain inaccessible to patients in the rest of the world," said Jess Lambe, VP and Managing Director of BioPharma Business Development, SOPHiA Genetics.

Myriad also plans to present PrGIS research, co-authored with AstraZeneca, at the European Society for Medical Oncology Congress 2026. The research is expected to further characterize the biomarker and support its validation, with full data to be available following the ESMO embargo period.